Nanoparticle-based therapy for respiratory diseases

Anais da Academia Brasileira de Ciencias

Volumn 85, Issue 1, 2013, Pages 137-146

  Da Silva, Adriana L ^a   Santos, Raquel S ^a   Xisto, Débora G ^a   Alonso, Silvia Del V ^b   Morales, Marcelo M ^a   Rocco, Patricia Rieken Macedo ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b UNIVERSIDAD NACIONAL DE QUILMES   (Argentina)

Author keywords

Asthma; Lung cancer; Nanotechnology; Turberculosis

Indexed keywords

NANOPARTICLE;

ASTHMA; DRUG DELIVERY SYSTEM; HUMAN; LUNG DISEASE; LUNG TUBERCULOSIS; LUNG TUMOR; METHODOLOGY; REVIEW;

ASTHMA; DRUG DELIVERY SYSTEMS; HUMANS; LUNG DISEASES; LUNG NEOPLASMS; NANOPARTICLES; TUBERCULOSIS, PULMONARY;

EID: 84875395529     PISSN: 00013765     EISSN: 16782690     Source Type: Journal    
DOI: 10.1590/S0001-37652013005000018     Document Type: Review

References (54)

1. Abu-Dahab R, Schaefer UF and Lehr CM. 2001. Lectinfunctionalized liposomes for pulmonary drug delivery: Effect of nebulization on stability and bioadhesion. Eur J Pharm Sci 1: 37-46.
2. Anabousi S, Laue M, Lehr CM, Bakowsky U and Ehrhardt C. 2005. Assessing transferring modification of lipossomes by atomic force microscopy and transmission electron microscopy. Eur J Pharm Biopharm 2: 295-303.
3. Bailey MM and Berkland CJ. 2009. Nanoparticle formulations in pulmonary drug delivery. Med Res Rev 29: 196-212.
4. Bakan DA, Weichert JP, Longino MA and Counsel RE. 2000. Polyiodinated triglyceride lipid emulsions for use as hepatoselective contrast agents in CT. Investigative Radio 35: 158-169.
5. Beck-Broichsiter M, Gaus J, Gesler T, Seeger W, Kisel T and Schmehl T. 2010. Pulmonary targeting with biodegradable salbutamol-loaded nanoparticles. J Aerosol Med Pulm Drug Deliv 23(1): 47-57.
6. Bhaskar S et al. 2010. Multifunctional nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging. Part Fibre Toxicol 7: 3.
7. Bhavna, Ahmad FJ, Mital G, Jain GK, Malhotra G, Khar RK and Bhatnagar A. 2009. Nano-salbutamol dry powder inhalation: A new approach for treating broncho-constrictive conditions. Eur J Pharm Biopharm 71: 282-291.
8. Bur M, Hening A, Hein S, Schneider M and Lehr CM. 2009. Inhalative nanomedicine-opportunities and challenges. Inhal Toxicol 21:137-143.
9. Card JW, Zeldin DC, Boner JC and Nestman ER. 2008. Pulmonary applications and toxicity of engineered nanoparticles. Am J Physiol Lung Cell Mol Physiol 295: 400-411.
10. Chiaramoni NS, Gasparri J, Speroni L, Taira MC and Alonso S del V. 2010. Biodistribution of liposome/ DNA systems after subcutaneous and intraperitoneal inoculation. J Liposome Res 20: 191-201.
11. Choi JW, Oh BK, Kim YK and Min J. 2007. Nanotechnology in biodevices. J Microbiol Biotechnol 17: 5-14.
12. De Jong WH and Borm PJ. 2008. Drug delivery and nanoparticles: Applications and Hazards. Int J Nanomedicine 3: 133-149.
13. DiMarco M, Shamsudin S, Razak KA, Aziz AA, Devaux C, Borghi E, Levy L and Sadun C. 2010. Overview of the main methods used to combine proteins with nanosystems: absorption, bioconjugation, and encapsulation. Int J Nanomedicine 5: 37-49.
14. El-Gendy N, Gorman EM, Munson EJ and Berkland C. 2009. Budesonide nanoparticle agglomerates as dry powder aerosols with rapid dissolution. J Pharm Sci 98(8): 2731-2746.
15. Feynman RP. 1992. There is plenty rooms at the bottom. J Microelec Tromech Syst 1: 60-66.
16. Freitas Jr RA. 1998. Exploratory design in medical nanotechnology: a mechanical artificial red cell. Artif Cells Blood Substit Immobil Biotechnol 26(4): 411-430.
17. Gelperina S, Kisich K, Iseman MD and Heifets L. 2005. The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am J Respir Crit Care Med 172: 1487-1490.
18. Griset AP, Walpole J, Liu R, Gafey A, Colson YL and Grinstaff MW. 2009. Expansile nanoparticles: synthesis, characterization, and in vivo efficacy of an acidresponsive polymeric drug delivery system. J Am Chem Soc 131: 2469-2471.
19. Guthi JS et al. 2010. MRI-visible micellar nanomedicine for targeted drug delivery to lung cancer cells. Mol Pharm 7: 32-40.
20. Harington KJ, Rowlinson-Busza G, Syrigos KN, Uster PS, Abra RM and Stewart JSW. 2000. Biodistribution and pharmacokinetics of 111In-DTPA-labelled pegylated liposomes in a human tumour xenograft model: implications for novel targeting strategies. Brit J Cancer 83: 232-238.
21. Harush-Frenkel O et al. 2010. A safety and tolerability study of differently-charged nanoparticles for local pulmonary drug delivery. Toxicol Appl Pharmacol 246(1-2): 83-90.
22. Hitzman CJ, Wattenberg LW and Wiedman TS. 2006. Pharmacokinetics of 5-Fluorouracil in the hamster following inhalation delivery of lipid-coated nanoparticles. J Pharm Sci 95: 1196-1211.
23. Iga AM, Robertson JH, Winslet MC and Seifalian AM. 2007. Clinical potential of quantum dots. J Biomed Biotechnol 2007: 76087-76097.
24. Kim SC, Kim DW, Shim YH, Bang JS, Oh HS, Wan Kim S and Seo MH. 2001. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. J Control Release 72: 191-202.
25. Kimura S et al. 2009. Nanoparticle-mediated delivery of nuclear factor kappaB decoy into lungs ameliorates monocrotaline-induced pulmonary arterial hypertension. Hypertension 53(5): 877-883.
26. Kong X, Helerman GR, Zhang W, Jena P, Kumar M, Behera A, Lockey R and Mohapatra SS. 2008. Chitosan interferon-γ nanogene therapy for lung disease: modulation of T-cell and dendritic cell immune responses. Allergy Asthma Clin Immunol 4: 95-105.
27. Krause W. 1999. Delivery of diagnostic agents in computed tomography. Adv Drug Delivery Rev 37: 159-173.
28. Kroegel C. 2009. Global Initiative for Asthma (GINA) guidelines: 15 years of application. Expert Rev Clin Immunol 5(3): 239-249.
29. Kumar M, Kong X, Behera AK, Helerman GR, Lockey RF and Mohapatra SS. 2003. Chitosan IFN-γ-pDNA Nanoparticle (CIN) therapy for allergic asthma. Genet Vaccines Ther 1: 3.
30. Lai SK, O'hanlon ED, Man ST, Cone R and Hanes J. 2005. Real-time transport of polymer nanoparticles in cervical vaginal mucus. AIChE Ann Meeting Conf Proceedings, p. 14298.
31. Li C et al. 2009. PAMAM nanoparticles promote acute lung injury by inducing autophagic cell death through the Akt-TSC2-mTOR signaling pathway. J Mol Cell Biol 1: 37-45.
32. Liu M, Zhang H and Slutsky AS. 2009. Acute lung injury: a yellow card for engineered nanoparticles? J Mol Cell Biol 1: 6-7.
33. Luten J, Van Nostrum CF, De Smedt SC and Henink WE. 2008. Biodegradable polymers as non-viral carriers for plasmid DNA delivery. J Control Release 2: 97-110.
34. Ma Y, Zheng Y, Liu K, Tian G, Tian Y, Xu L, Yan F, Huang L and Mei L. 2010. Nanoparticles of Poly(Lactide-Co-Glycolide)-d-a-Tocopheryl Polyethylene Glycol 1000 Succinate Random Copolymer for cancer treatment. Nanoscale Res Lett 5: 1161-1169.
35. Mansour HM, Rhe YS and Wu X. 2009. Nanomedicine in pulmonary delivery. Int J Nanomedicine 4: 299-319.
36. Matsuo Y, Ishihara T, Ishizaki J, Miyamoto K, Higaki M and Yamashita N. 2009. Effect of betamethasone phosphate loaded polymeric nanoparticles on a murine asthma model. Cell Immunol 260: 33-38.
37. McMahon GT and Arky RA. 2007. Inhaled insulin for diabetes mellitus. N Engl J Med 356: 497-502.
38. Pandey R and Khuler GK. 2004. Subcutaneous nanoparticlebased antitubercular chemotherapy in an experimental model. J Antimicrob Chemother 54: 266-268.
39. Pandey R, Sharma A, Zahor A, Sharma S, Khuler GK and Prasad B. 2003. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother 52: 981-986.
40. Pison U, Welte T, Giersig M and Groneberg DA. 2006. Nanomedicine for respiratory diseases. Eur J Pharmacol 533: 341-350.
41. Saraogi GK, Gupta P, Gupta UD, Jain NK and Agrawal GP. 2010. Gelatin nanocarriers as potential vectors for effective management of tuberculosis. Int J Pharm 385(1-2): 143-149.
42. Sharma A, Sharma S and Khuler GK. 2004. Lectinfunctionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis. J Antimicrob Chemother 54: 761-766.
43. Stern ST and McNeil SE. 2008. Nanotechnology safety concerns revisited. Toxicol Sci 101: 4-21.
44. Stone V, Johnston H and Clift MJ. 2007. Air pollution, ultrafine and nanoparticle toxicology:celular and molecular interactions. IEEE Trans Nanobioscience 6: 331-340.
45. Surendiran A, Sandhiya S, Pradhan SC and Adithan C. 2009. Novel applications of nanotechnology in medicine. Indian J Med Res 130: 689-701.
46. Tang BC et al. 2009. Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier. Proc Natl Acad Sci USA 106: 19268-19273.
47. Taylor DL, Woo ES and Giuliano KA. 2001. Real-time molecular and cellular analysis: the new frontier of drug discovery. Curr Opin Biotechnol 12: 75-81.
48. Usmani OS, Bidiscombe MF and Barnes PJ. 2005. Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size. Am J Resp Crit Care Med 172: 1497-1504.
49. Warheit DB, Borm PJ, Henes C and Lademan J. 2007. Testing strategies to establish the safety of nanomaterials: conclusions of an ECETOC workshop. Inhal Toxicol 19: 631-643.
50. Watson P, Jones AT and Stephens DJ. 2005. Intracellular trafficking pathways and drug delivery: fluorescence imaging of living and fixed cells. Adv Drug Deliv Rev 57: 43-61.
51. Watt AP, Morison II and Evans DC. 2000. Approaches to higher-throughput pharmacokinetics (HTPK) in drug discovery. Drug Discov Today 5: 17-24.
52. Yih TC and Al-Fandi M. 2006. Engineered nanoparticles as precise drug delivery systems. J Cell Biochem 97: 1184-1190.
53. Ziady AG et al. 2003. Transfection of airway epithelium by stable PEGylated Poly-l-Lysine DNA nanoparticles in vivo. Mol Ther 8: 936-947.
54. Zahor A, Sharma S and Khuler GK. 2005. Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis. Int J Antimicrob Agents 26: 298-303.